ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42
for the treatment of Pulmonary Arte
DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to the Company's lead clinical candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH). The European Commission formally adopted this decision on
ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress Showca
DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), announced today that its Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will deliver a corporate showcase presentation at the 2018 Biotech & Money / Medtech & Money World Congress in London, England, Tuesday, February 6, 2018 at 12:3
